<DOC>
	<DOC>NCT00534183</DOC>
	<brief_summary>"No clinical differences will be found between the three antipsychotics under study - olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight. "</brief_summary>
	<brief_title>Metabolic Profile and Anthropometric Changes in Schizophrenia</brief_title>
	<detailed_description>we aimed to study the effects of antipsychotics, olanzapine, risperidone and haloperidol on development of metabolic syndrome in a drug na√Øve population suffering from first episode schizophrenia and compared it with a matched healthy control group. We also aimed to examine the prevalence of metabolic syndrome as defined by the two most widely accepted definitions, the ATP IIIA and the IDF.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Age between 1840 years Diagnosis of schizophrenia Drug naive on admission Other psychiatric comorbidity History of severe physical illness Alcohol and substance abuse or dependence History of preexisting diabetes or hypertension Family history of hypertension or diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Obesity</keyword>
	<keyword>Diabetes</keyword>
</DOC>